Friday, 06 Dec 2019

You are here

EXCEED Study: Cosentyx Equals Humira in Psoriatic Arthritis

Novartis has announced the results of the EXCEED trial that pitted its IL-17 inhibitor, Cosentyx (secukinumab - SEC) against Humira (adalimumab - ADA) in patients with active psoriatic arthritis (PsA). The trial demonstrated that SEC was not non-inferior to ADA, but failed to meet it's primary endpoint of superiority over ADA as far as drug efficacy.  

EXCEED was novel in that it was the first double-blinded head-to-head clinical trial comparing SEC (300 mg loading regimen; then every 4 weeks) against ADA (40 mg given every other week). This was a 52-week, Phase IIIb trial that enrolled over 800 biologic-naïve patients with PsA. The primary endpoint was to be the efficacy of SEC, showing superiority, over ADA as assessed by ACR20 response rates at Week 52. 

The results will be presented at an upcoming major medical meeting. Nonetheless, the pre-release suggests that SEC narrowly missed statistical significance for superiority in ACR 20. For many of the secondary measures it showed numerically higher results versus ADA and there were no new safety signals generated for either agent in this study.

Equivalence between a TNF inhibitor and IL-17 inhibitor was also shown last month in an ARD article wherein Taltz (ixekizumab) had equal ACR50 (51% vs 47%) in PsA, yet IXE outperformed ADA for skin (PASI100) responses (60% vs 47%).

Thus, SEC demonstrates equivalent efficacy in managing the articular disease of PsA, especially when given to biologic naive patients. 

Cosentyx is currently FDA approved for use in psoriatic arthritis, psoriasis and ankylosing spondylitis, and has been given to over 250,000 patients worldwide.

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Secukinumab Improves Enthesitis

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week. 

Spondyloarthritis Affects Pregnancy Outcomes

A Danish registy has shown that the the prevalence of Spondyloarthritis (SpA) diagnosed prior to delivery has increased 5 fold in the last two decades and that SpA is associated with an increased risk of adverse pregnancy outcomes (APO).

IL-17 Inhibitors In Non-Radiographic Axial SpA

This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.

Psoriatic Arthritis at ACR 2019

Below are several of the highlight studies in psoriatic arthritis (PsA) presented at the ACR 2019 annual meeting in Atlanta. 

New Treatments in Axial SpA from #ACR2019

There were new developments in the treatment of axial Spondyloarthritis (AS) at ACR 2019. The first area is on the use of anti-IL17A drugs, secukinumab and ixekizumab in non-radiographic AS. The second area is the use of JAK-1 inhibitor Upadacitinib in radiographic AS. The third area is the use of dual anti-IL17A and 17F drug bimekizumab in radiographic.